Back
 PP  Vol.3 No.1 , January 2012
Cannabis Responsive Head Injury Induced Mutiple Disabilities: A Case Report
Abstract: In recent years cannabinoids and their derivatives have drawn renewed attention because of their diverse pharmacologic activities. We report here one such case, where all types of medical & psychiatric treatment failed to improve the symptoms; however cannabis use was able to bring back this patient to normal productive & meaningful life. The patient was a 47 year old left handed Caucasian had minor subdural hematoma at the posterior vertex and a minor focal subarachnoid haemorrhage following a physical assault. His impairments included cognitive slowing with decreased short term memory, organized skill & language deficit. His physical disabilities included spastic gait (hemiplegic), VII nerve palsy, mild cerebellar dysfunction, blurred vision and easy fatigue. He was unable to return to work or drive. In addition to cognitive deficit, right hemi paresis & dizziness; he had symptoms of anxiety & depression. Cannabis improved his gait and brought back lots of his memory. Within 6 months all his symptoms abated with use of cannabis and he started to look at cannabis as a real medicine. Slowly he also had improvement in cognitive functions, memory, vocabulary and his gait became increasingly better day by day with continued use of cannabis.
Cite this paper: M. Sharma, "Cannabis Responsive Head Injury Induced Mutiple Disabilities: A Case Report," Pharmacology & Pharmacy, Vol. 3 No. 1, 2012, pp. 58-61. doi: 10.4236/pp.2012.31009.
References

[1]   K. R. Muller-Vahl, H. Prevedel, K. Theloe, H. Kolbe, H. M. Emrich and U. Schneider, “Treatment of Tourette syndrome with Delta-9-Tetrahydrocannabinol (D9-THC): No Influence on Neuropsychological Performance,” Neuropsychopharmacology, Vol. 28, 2003, pp. 384-388. doi:10.1038/sj.npp.1300047

[2]   C. M. Coulston, M. Perdices and C. C. Tennant, “The Neuropsychological Correlates of Cannabis Use in Schizophrenia Lifetime Abuse/Dependence, Frequency of Use, and Recency of Use,” Schizophrenia Research, Vol. 96, No. 1-3, 2007, pp. 169-184. doi:10.1016/j.schres.2007.08.006

[3]   M. Herkenham, A. B. Lynn, M. D. Little, M. R. Johnson, L. S. Melvin, B. R. de Costa, et al., “Cannabinoid Receptor Localization in Brain,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, 1990, pp. 1932-1936.

[4]   R. J. McKallip, M. Nagarkatti and P. S. Nagarkatti, “Delta-9-tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response,” Journal of Immunol-ogy, Vol. 174, No. 6, 2005, pp. 3281-3289.

[5]   S. A. Wolf, A. Bick-Sander, K. Fabe, P. Leal-Galicia, et al., “Cannabinoid Receptor CB1 Mediates Baseline and Activity-Induced Survival of New Neurons in Adult Hippo-campal Neurogenesis,” Cell Communication and Signaling, Vol. 8, 2010, p. 12.

[6]   A. W. Zuardi, “Cannabidiol: From an Inactive Cannabinoid to a Drug with Wide Spec-trum of Action,” Revista Brasileira de Psiquiatria, Vol. 30, No. 3, 2008, pp. 271- 280. doi:10.1590/S1516-44462008000300015

[7]   T. V. Zanelati, C. Biojone, F. A. Moreira, F. S. Guimar?es and S. R. Joca, “Antidepressant Like Effects of Cannabidiol in Mice: Possible Involvement of 5-HT1 Areceptor,” British Journal of Pharmacology, Vol. 159, No. 1, 2010, pp. 122-128. doi:10.1111/j.1476-5381.2009.00521.x

[8]   V. M. Saito, C. T. Wotjak and F. A. Moreira, “Pharmacological Ex-ploitation of the Endocannabinoid System: New Perspec-tives for the Treatment of Depression and Anxiety Disor-ders?” Revista Brasileira de Psiquiatria, Vol. 32, Suppl. 1, 2010, pp. 7-14.

 
 
Top